Navigation Links
'SIRT(ain)' benefit of reducing calories
Date:10/10/2011

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin. Substantially reducing caloric intake enhances the sensitivity of skeletal muscle to insulin. Defining the molecular signals within skeletal muscle linking caloric restriction to improved insulin action could provide new targets for therapeutics to reduce insulin resistance and thereby lower an individual's risk of developing type 2 diabetes. In this context, a team of researchers led by Jerrold Olefsky, at the University of California at San Diego, La Jolla, has now found that the mouse protein Sirt1 has an integral role within skeletal muscle in linking caloric restriction to improved insulin action. Furthermore, they have identified the downstream molecular mechanism by which Sirt1 translates decreases in nutrient intake into enhanced skeletal muscle insulin sensitivity.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Frequent doctor visits benefits patients with diabetes
2. More Frequent Doctor Visits May Benefit Diabetes Patients
3. Benefits of radionuclide therapy for neuroendocrine tumors
4. High-risk, underserved women benefited from MRI screening for breast cancer
5. Dementia Patients Seem to Benefit From Small Group Homes
6. Prasugrel: Indications of an additional benefit for some patients, but also of greater harm
7. Older Women Can Benefit From Sex Ed Campaigns
8. Rural Stroke Victims May Benefit From Virtual Care
9. Muscle Training May Benefit Chronic Heart Failure Patients
10. World Alzheimers Report 2011: The benefits of early diagnosis and intervention
11. Trust in your neighbors could benefit your health, MU study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
(Date:7/20/2017)... ... July 20, 2017 , ... LINET, an international leader ... to their product line: the AVE 2 birthing bed. , Perfectly suitable for labor, ... new level of comfort and efficiency to every phase of childbirth. The AVE 2 ...
(Date:7/20/2017)... TX (PRWEB) , ... July 19, 2017 , ... At ... the availability of temporomandibular joint (TMJ) treatment and dental implants in Waco, ... TRIOS® intraoral scanner and the T-Scan™ by Tekscan®, they can capture details in the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson ... healthcare project manager, Josh Christensen. As a leader in healthcare construction, AP has ... its healthcare resume in the Midwest with Josh now on board. , ...
(Date:7/20/2017)... ... ... a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of published author, Carol ... summa cum laude graduate of Gardner Webb University. She has won numerous awards during ... public school, Lynn continued to pursue her love for music through playing piano, harp, ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
Breaking Medicine Technology: